Details

IRB Study Number 18-326

Status Recruiting

Institute Neurological Institute

Description

Description

We are doing this study to find out whether it is better to use highly effective medications early or if it is better to start with less powerful medications and escalate as needed. This study last about 36 months and requires a total of 5 visits to the Mellen Center. Study participants are randomly assigned to choose among early highly effective treatments or an escalation approach (any other approved multiple sclerosis medication). There is an equal chance of being in either of these groups. The individual medication you start within each group will be up to you and your neurologist.

Inclusion Criteria

Inclusion Criteria

  • Are between the ages of 18-60 years old
  • Considering starting a treatment for MS
  • Have been diagnosed with relapsing remitting multiple sclerosis
  • Relapses (attacks) or new brain lesions over the last 12 months
  • Able to walk independently or with assistance

Exclusion Criteria

Exclusion Criteria

  • Participants with contraindications to all forms of DMT in either of the treatment arms
  • Contraindication or inability to undergo MRI with Gd due to metal or metal implants, allergy to Gd contrast, claustrophobia, pain, spasticity, or excessive movement related to tremor